MIRAMAR, Fla., July 26, 2021 (GLOBE NEWSWIRE) -- G
Post# of 36537
Anthony J. Dolisi, President and Chief Executive Officer of Olaregen said, “This is an exciting day for Excellagen, as we now have opened door for international distribution channels to do business in Asia. This Distribution Agreement will also open the door to conduct business in Singapore, Thailand, Indonesia, Vietnam, Philippines, and other countries in Southeast Asia where the market for wound care products is expanding with rising income levels, increasing incidence of diabetes, and improved patient access.”
Cliff Keeling, Vice President and Chief Operating Officer of Olaregen said, “Nexgen Medical has well established connections throughout the orthopedic and podiatry communities in Malaysia, and we are very excited to work with them on our expansion into Asia. The Life Science industry in Malaysia is one of the new growth areas targeted for promotion and development by the government, so we look forward to great success.”
About Generex Biotechnology Corp.
Generex Biotechnology is an integrated healthcare holding company with end-to-end solutions for patient centric care from rapid diagnosis through delivery of personalized therapies. Generex is building a new kind of healthcare company that extends beyond traditional models providing support to physicians in an MSO network, and ongoing relationships with patients to improve the patient experience and access to optimal care.
About Olaregen Therapeutix
Olaregen Therapeutix, Inc. is a regenerative medicine company focused on the development, manufacturing and commercialization of products that fill unmet needs in the current wound care market. The company aims to provide advanced healing solutions that substantially improve medical outcomes while lowering the overall cost of care. Olaregen's first product introduction, Excellagen® (flowable dermal matrix) is a topically applied product for dermal wounds and other indications. Excellagen is an FDA 510K cleared device for a broad array of dermal wounds, including partial and full thickness wounds, pressure ulcers, venous ulcers, diabetic ulcers, chronic vascular ulcers, tunneled/undermined wounds, surgical wounds (donor sites/ grafts, post-Mohs surgery, post-laser surgery, podiatric, wound dehiscence), trauma wounds (abrasions, lacerations, second-degree burns, and skin tears) and draining wounds, enabling Olaregen to market Excellagen in multiple vertical markets. in bone and joint regeneration comprise the current pipeline. The company's mission is to become a significant force in regenerative medicine and advance the science of healing.